Read by QxMD icon Read


Mehmet Sitki Copur, Julie Marie Wurdeman, Debra Nelson, Ryan Ramaekers, Dron Gauchan, David Crockett
Solid tumors involving glandular organs express mucin glycoprotein which is eventually shed into the circulation. As aresult these proteins can easily be measured in the serum and be used as potential tumor markers. The most commonly used tumor markers for breast cancer are CA 27-29 and CA 15-3, which both measure the glycoprotein product of the mucin-1 (MUC1) gene. CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in breast cancer patients. Most oncology clinical practice guidelines do not recommend the use of tumor markers for routine surveillance of early stage disease but recognize their utility in the metastatic setting...
December 11, 2017: Oncology Research
Sinead A Noonan, Tejas Patil, Dexiang Gao, Gentry G King, Jessica R Thibault, Xian Lu, Paul A Bunn, Robert C Doebele, W Thomas Purcell, Anna E Barón, D Ross Camidge
INTRODUCTION: The role of serum tumor markers in the modern management of advanced NSCLC remains poorly described. METHODS: A single-center retrospective analysis of available carcinoembryonic antigen, CA125, CA19.9, and CA27.29 levels at baseline and during treatment of stage IV lung adenocarcinoma by oncogenic driver was conducted. RESULTS: A total of 142 patients were analyzed (60 with anaplastic lymphoma kinase gene [ALK] rearrangement, 50 with EGFR mutation, four with ROS1 rearrangement, and 29 with KRAS mutation)...
January 2018: Journal of Thoracic Oncology
Philip Hepp, Ulrich Andergassen, Bernadette Jäger, Elisabeth Trapp, Marianna Alunni-Fabbroni, Thomas W P Friedl, Nadeschda Hecker, Ralf Lorenz, Peter Fasching, Andreas Schneeweiss, Tanja Fehm, Wolfgang Janni, Brigitte Rack
BACKGROUND: Evidence for the prognostic value of circulating tumor cells (CTCs) in early-stage breast cancer is swiftly increasing. An alternative approach for identifying patients at risk for recurrence is based on the detection of the mucin-1 (MUC1)-based tumor marker CA27.29. Here we report the association of these two prognostic markers before and immediately after chemotherapy (CHT), as well as after 2 and 5 years of follow-up. PATIENTS AND METHODS: The SUCCESS trial compared fluorouracil, epirubicin and cyclophosphamide followed by docetaxel vs...
2016: Anticancer Research
Radwa Ewaisha, Chelsea D Gawryletz, Karen S Anderson
Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse...
2016: Expert Review of Proteomics
Andrea Nicolini, Paola Ferrari, Giuseppe Rossi
Structural and functional characteristics of mucins and cytokeratins are shortly described. Thereafter, those commonly used in breast cancer as serum tumor markers are considered. First CA15.3, MCA, CA549, CA27.29 mucins and CYFRA21.1, TPA, TPS cytokeratins alone or in association have been examined in different stages and conditions. Then their usefulness in monitoring disease-free breast cancer patients is evaluated. The central role of the established cut-off and critical change, the "early" treatment of recurrent disease and the potential benefit in survival are other issues that have been highlighted and discussed...
2015: Advances in Experimental Medicine and Biology
Ming Li, Jeon Woong Kang, Saraswati Sukumar, Ramachandra Rao Dasari, Ishan Barman
Circulating biomarkers have emerged as promising non-invasive, real-time surrogates for cancer diagnosis, prognostication and monitoring of therapeutic response. Emerging data, however, suggest that single markers are inadequate in describing complex pathologic transformations. Architecting assays capable of parallel measurements of multiple biomarkers can help achieve the desired clinical sensitivity and specificity while conserving patient specimen and reducing turn-around time. Here we describe a plasmon-enhanced Raman spectroscopic assay featuring nanostructured biomolecular probes and spectroscopic imaging for multiplexed detection of disseminated breast cancer markers cancer antigen (CA) 15-3, CA 27-29 and cancer embryonic antigen (CEA)...
July 1, 2015: Chemical Science
Nina Mikirova, Joseph Casciari, Andrea Rogers, Paul Taylor
BACKGROUND: An inflammatory component is present in the microenvironment of most neoplastic tissues. Inflammation and elevated C-reactive protein (CRP) are associated with poor prognosis and decreased survival in many types of cancer.Vitamin C has been suggested as having both a preventative and therapeutic role in a number of pathologies when administered at much higher-than-recommended dietary allowance levels.Since in vitro studies demonstrated inhibition of pro-inflammatory pathways by millimolar concentrations of vitamin C, we decided to analyze the effects of high dose IVC therapy in suppression of inflammation in cancer patients...
September 11, 2012: Journal of Translational Medicine
Udo Jeschke, Irmi Wiest, Anamur Lan Schumacher, Markus Kupka, Brigitte Rack, Renate Stahn, Uwe Karsten, Doris Mayr, Klaus Friese, Darius Dian
AIM: Mucin 1 (MUC1) is a high molecular weight transmembrane glycoprotein with unique properties which is used as a tumour marker in sera of ovarian cancer patients. The common test kit for the cancer antigen 15-3 (CA15-3) is not sufficient for the discrimination between sera from healthy individuals and sera from patients with benign changes of the ovaries. In this study, the newly developed anti-MUC1 antibody PankoMab was tested in normal and patient sera with an ELISA, and the obtained data were compared against data from experiments using the commercial kits for CA15-3 and CA27...
May 2012: Anticancer Research
Maj Kristin Freydanck, Ruediger Paul Laubender, Brigitte Rack, Lan Schuhmacher, Udo Jeschke, Christoph Scholz
BACKGROUND: When caring for patients with ovarian neoplasms, correct preoperative discrimination of benign and malignant disease is deemed vital. In this study, we tested serum biomarkers' alone and in combination, to achieve this aim. MATERIALS AND METHODS: We measured the concentrations of Cancer Antigen (CA)-125, CA15-3, CA27-29, Carcinoembryonic Antigen (CEA), CA19-9, human chorionic gonadotropin (hCG), Placental Protein (PP)1490, CA72-4, galectin-3, galectin-1 and Human epididymis protein (HE)4 in sera of 133 patients with pelvic masses by ELISA and correlated the results to subsequent histology...
May 2012: Anticancer Research
Rahber Thariani, William Wong, Josh J Carlson, Louis Garrison, Scott Ramsey, Patricia A Deverka, Laura Esmail, Sneha Rangarao, Carolyn J Hoban, Laurence H Baker, David L Veenstra
BACKGROUND: Systematic approaches to stakeholder-informed research prioritization are a central focus of comparative effectiveness research. Genomic testing in cancer is an ideal area to refine such approaches given rapid innovation and potentially significant impacts on patient outcomes. OBJECTIVE: To develop and pilot test a stakeholder-informed approach to prioritizing genomic tests for future study in collaboration with the cancer clinical trials consortium SWOG...
May 2012: Medical Care
Dapeng Zhou, Steven B Levery, Fong-Fu Hsu, Peng G Wang, Susann Teneberg, Igor C Almeida, Yunsen Li, Huaxi Xu, Lai-Xi Wang, Chengfeng Xia, Nuhad K Ibrahim, Katja Michael
Cancer associated glycoconjugates are important biomarkers, as exemplified by globo-H, CA125, CA15.3 and CA27.29. However, the exact chemical structures of many such biomarkers remain unknown because of technological limitations. In this article, we propose the "immunologic mapping" of cancer glycomes based on specific immune recognition of glycan structures, which can be hypothesized theoretically, produced chemically, and examined biologically by immuno-assays. Immunologic mapping of glycans not only provides a unique perspective on cancer glycomes, but also may lead to the invention of powerful reagents for diagnosis and therapy...
2011: Frontiers in Bioscience (Scholar Edition)
Hui-Jen Chang, Ming-Je Yang, Yu-Hsiang Yang, Ming-Feng Hou, Er-Jung Hsueh, Shiu-Ru Lin
Within the past decade, the incidence of breast cancer in Taiwan has been rising year after year. Breast cancer is the first most prevalent cancer and the fourth leading cause of cancer-related deaths among women in Taiwan. The early stage of breast cancer not only have a wider range of therapeutic options, but also obtain a higher success rate of therapy than those with advanced breast cancer. A test for tumor markers is the most convenient method to screen for breast cancer. However, the tumor markers currently available for breast cancer detection include carcinoembryonic antigen (CEA), carbohydrate antigen 15...
November 2009: Oncology Reports
Putao Cen, Madeleine Duvic, Philip R Cohen, Razelle Kurzrock
BACKGROUND: Mycosis fungoides, also called cutaneous T-cell lymphoma, comprise a group of extranodal, indolent non-Hodgkin's lymphomas of T-cell origin with primary involvement of the skin. There are few data available on tumor markers in these patients. Cancer antigen 27.29 (CA27.29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer...
March 2008: Journal of the American Academy of Dermatology
Crystal Kirmiz, Bensheng Li, Hyun Joo An, Brian H Clowers, Helen K Chew, Kit S Lam, Anthony Ferrige, Robert Alecio, Alexander D Borowsky, Shola Sulaimon, Carlito B Lebrilla, Suzanne Miyamoto
Because the glycosylation of proteins is known to change in tumor cells during the development of breast cancer, a glycomics approach is used here to find relevant biomarkers of breast cancer. These glycosylation changes are known to correlate with increasing tumor burden and poor prognosis. Current antibody-based immunochemical tests for cancer biomarkers of ovarian (CA125), breast (CA27.29 or CA15-3), pancreatic, gastric, colonic, and carcinoma (CA19-9) target highly glycosylated mucin proteins. However, these tests lack the specificity and sensitivity for use in early detection...
January 2007: Molecular & Cellular Proteomics: MCP
Michael J Duffy
BACKGROUND: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA. METHODS: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels...
March 2006: Clinical Chemistry
Betty S Pio, Cecilia K Park, Richard Pietras, Wei-Ann Hsueh, Nagichettiar Satyamurthy, Mark D Pegram, Johannes Czernin, Michael E Phelps, Daniel H S Silverman
OBJECTIVE: The usefulness of 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-positron emission tomography (PET) in monitoring breast cancer response to chemotherapy has previously been reported. Elevated uptake of FDG by treated tumors can persist however, particularly in the early period after treatment is initiated. 3'-[F-18]Fluoro-3'-deoxythymidine (FLT) has been developed as a marker for cellular proliferation and, in principle, could be a more accurate predictor of the long-term effect of chemotherapy on tumor viability...
January 2006: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Xi Wang, Wei-Jiang Liang, Zhen-Yu Zhu, Ming-Tian Yang, Yi-Xin Zeng
BACKGROUND & OBJECTIVE: Pre-symptomatic screening of early-stage breast cancer may greatly reduce tumor-related mortality. Some tumor markers, such as CA15-3 and CA27-29, are recommended only for monitoring therapy of advanced or relapsed breast cancer. This study was to find new biomarkers that could be used individually or in combination with an existing modality for cost-effective screening of breast cancer by proteome analysis. METHODS: Protein expression differences among 128 serum samples of 64 breast cancer patients (19 of stage I, 24 of stage II, and 21 of stage III), 52 patients with benign breast diseases, and 12 healthy women were analyzed with IMAC3 and WCX2 Ciphergen ProteinChip Arrays...
November 2004: Ai Zheng, Aizheng, Chinese Journal of Cancer
Young Y Wang, Francis P Kuhajda, Jinong Li, Teia T Finch, Paul Cheng, Clare Koh, Tianwei Li, Lori J Sokoll, Daniel W Chan
Overexpression of fatty acid synthase (FAS EC is associated with certain cancers and therefore is a putative tumor marker. The presence of FAS in patients with breast, prostate, colon, ovarian, and other cancers has been reported. The mechanism of FAS overexpression in malignancies remains unknown. Here, we show that FAS is released into the extracellular space in cancer cells. The extracellular FAS are present in various immunoreactive forms, and show different expression patterns in various cancer cells...
July 2004: Journal of Experimental Therapeutics & Oncology
Harold J Burstein, George D Demetri, Elisabetta Mueller, Pasha Sarraf, Bruce M Spiegelman, Eric P Winer
PURPOSE: To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer. EXPERIMENTAL DESIGN: Patients with advanced breast cancer refractory to at least one chemotherapy regimen (ER negative tumors) or two hormonal regimens (ER positive tumors) were treated with troglitazone at 800 mg p.o. QD until disease progression, to determine the percentage of patients free of progression at 6 months...
June 2003: Breast Cancer Research and Treatment
D Lüfter, A Richter, S Günther, B Flath, C Akrivakis, R Geppert, K D Wernecke, K Possinger
BACKGROUND: The assessment of bone metastases by clinical examination or imaging techniques is still considered unreliable. We compared a specific marker of bone resorption, urinary deoxypyridinoline (DPD)-crosslinks, with serum calcium (Ca), alkaline phosphatase (AP) and CA27.29, to evaluate the status of bone metastases in patients with breast cancer. MATERIALS AND METHODS: Second morning voided urine was collected from 2 groups of patient (pts), those without evidence of disease (n = 118), and those with bone metastases (n = 85) under specific therapy plus pamidronate...
November 2000: Anticancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"